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SDX group, their average costs per hospitalization were
less ($8,145 versus $18,617) in part due to shorter ALOS
(7.9 versus 14.3 days). Costs due to rehabilitation (8%
versus 3%) and other services including surgical care and
cast room (20% versus 5%) were higher in the SDX
group, presumably due to 85% of these patients receiving
acute rehabilitation, fractures, or falls related diagnoses.
For both groups, nursing care was the major cost driver
(73% and 58%). Services including radiology, labora-
tory, pharmacy, EKG, EEG, and EMG totaled 19% and
14% of the PDX and SDX group costs, respectively.
CONCLUSION: The study found that most patients
were admitted for the treatment of Parkinson’s disease–
related (secondary) diagnoses rather than for primary di-
agnosis of Parkinson’s disease. Providing better care at
home and applying appropriate safety precautions may
potentially impact a portion of these admissions and re-
duce associated resource use.
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OBJECTIVE: We estimated savings in the cost of caring
for Alzheimer’s disease patients during 6 months, 1 year,
and 2 years treatment with rivastigmine. An intermediate
objective was to estimate the relationship between dis-
ease progression and institutionalization.
METHODS: We assessed the relationship between Mini-
Mental State Examination (MMSE) score and institutional-
ization using a piecewise Cox proportional hazard model.
To estimate cost savings from treatments lasting 6 months,
1 year, and 2 years, estimates of the probability of institu-
tionalization were integrated with data from a 6-month,
Phase III clinical trial of rivastigmine and a hazard model
of disease progression.
RESULTS: Our data suggest that savings in the overall
cost of caring for patients with mild and moderate AD
can be as high as $4839.00 per patient after 2 years treat-
ment. Further, the probability of institutionalization in-
creases steadily as MMSE score falls. Among our study
subjects age, race, level of education, and marital status
were significant predictors of institutionalization, while
gender had little effect.
CONCLUSION: Using rivastigmine in treating Alzhe-
imer’s disease results in a delay in disease progression for
patients who begin treatment during the mild or moder-
ate stages of the disease. By delaying the probability that
a patient will be institutionalized, the cost of caring for
AD patients can be significantly reduced.
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OBJECTIVE: We developed and then validated a self-
administered health-related quality of life survey for indi-
viduals with schizophrenia living in the community as
part of the Schizophrenia Outcomes Assessment Project
(SOAP).
METHODS: Fifteen hundred adult consumers with schizo-
phrenia (61% male) were recruited from five states (AZ,
MA, SC, WA, WI). Consumers completed four adminis-
trations of a 51-item survey assessment in 3 months. A
staff version of consumer status was also completed at
each administration.
RESULTS: Factor analysis, based on 1382 consumers
who answered all 51 items, supports eight factors: satis-
faction, self-concept, work/role, mental health, interper-
sonal, medication effects, activities of daily living, and
physical function. The combined score of the instrument
ranges from a low of 51 to a high of 204 with a popula-
tion mean of 150.6  20.2. Cronbach alpha of the
51-item survey is 0.9242 with all but one of the eight fac-
tors being over 0.700 (medication effects was 0.624).
Each item had a stronger correlation with its factor score
with that item removed than with other factors. Face and
content validity were established by an expert panel and
consumers. Convergent validity was established by com-
paring consumers’ global assessment of their status for
each factor to the companion actual factor scores; con-
gruence was significant (p  0.0001). Divergent validity
was established by comparing staffs’ placement of the
consumers into four levels of functionality for each of the
eight factors. Except for the medication effects factor, the
association between staff assessment and consumer fac-
tor scores was significant (p  0.0001).
CONCLUSION: The SOAP-51 is a valid and reliable
health-related quality of life instrument for use in a popu-
lation of individuals with schizophrenia living in the
community.
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Depression is a public health problem with a lifetime preva-
lence estimate over 17% and the second leading cause
of disease burden worldwide. Despite the existence of
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efficacious treatments such as pharmacotherapy and psy-
chotherapy, the effectiveness of care for depression is still
highly variable; many patients who start medication do not
complete the recommended treatment duration. To date,
little work has examined how people “value” depression.
OBJECTIVE: The study purpose was to assess and com-
pare utilities of patients with major depression and non-
depressed primary care patients for different depression
health states that incorporated treatment side effects. For
comparison, utilities for two HIV states were also obtained.
METHODS: Sixty-five patients with major depression
were interviewed before their first visit using two prefer-
ence assessment methods including the Standard Gamble.
Sixty-five non-depressed primary care patients were also
interviewed using matched (to the patient sample) de-
pression health states. The duration of all health states
presented was 1 year.
RESULTS: Preliminary results are from over 60% of the
sample. Several differences in utilities for depression states
between the two samples were obtained. First, severe un-
treated depression (SUD) had a median utility of 0.40 for
the depressed group and 0.55 for the non-depressed group.
Second, the depressed group’s current health had a mean
utility of 0.74 while the non-depressed group’s current
health had a utility of 0.91. For the depressed group, SUD
had a utility intermediate between the two HIV states
(0.51 and 0.30), while the non-depressed group rated SUD
higher (0.47) than the two HIV states (0.45 and 0.40).
CONCLUSIONS: While the depressed sample had lower
utilities than the non-depressed group, results from both
groups highlight the substantial impact depression has,
even within a 1-year duration, and compared to two HIV
states. This has important implications for quality of life
and pharmacoeconomic studies for depression.
ECONOMIC AND OUTCOMES ISSUES OF 
RESPIRATORY DISEASE
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TREATING ALLERGIC RHINITIS IN PATIENTS 
WITH COMORBID ASTHMA: THE RISK OF 
ASTHMA-RELATED HOSPITALIZATIONS AND 
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Evidence of the coexistence of asthma and allergic rhini-
tis has been broadly discussed in the literature.
 
OBJECTIVE:
 
 In this study, patients with both conditions
were studied and the hypothesis that treating allergic rhin-
itis reduces healthcare utilization for comorbid asthma
was tested.
 
METHODS:
 
 The study design was a retrospective cohort
study using 1994–1995 MarketScan® claims data. The
cohort was limited to patients age 12–60 who were contin-
uously enrolled and had no evidence of chronic obstructive
pulmonary disease. Allergy treatment and asthma events
(hospitalizations and emergency room visits) were identi-
fied. To estimate the magnitude of the association between
allergy treatment and asthma events, we calculated an inci-
dence density ratio (IDR) associated with exposure to aller-
gic rhinitis treatment. A multivariate Poisson regression was
estimated and the parameter estimates were transformed
into IDRs for each explanatory variable. An allergic rhinitis
treatment indicator was included in all regressions.
RESULTS: The final study population consisted of 4944
allergic asthmatics approximately 73% of whom were
treated for their allergies. Asthma related events were
more frequent in the untreated group compared to the
treated, 6.6% compared to 1.3%. An IDR of 0.49 for the
treatment group (p  0.001) indicates that the risk of an
asthma related event for the treated group was about half
that of the untreated group.
CONCLUSION: Overall, we found that those who were
treated for allergic rhinitis have a significantly lower risk
of subsequent asthma related events (ER visits or hospi-
talizations) than those who were not treated.
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Given the increasing number of therapies, purchasers and
payers of healthcare are becoming more sensitive to the
overall cost of treatment in relation to the clinical out-
comes achieved.
OBJECTIVE: The purpose of this economic analysis was
to compare the value of an inhaled corticosteroid (ICS),
fluticasone propionate 88mcg twice daily, versus a leu-
kotriene receptor antagonist (LTRA), zafirlukast 20mg
twice daily, in subjects with persistent asthma currently
receiving short acting beta2-agonists alone.
METHODS: The data utilized in the analyses was col-
lected from a multicenter, randomized, double-blind, dou-
ble-dummy, parallel group, placebo-controlled clinical
trial. Effectiveness parameters included in this economic
analysis were the proportion of symptom-free days (SFD),
and QoL improvements (0.5 change from baseline). Di-
rect costs (D) included: costs of study drugs, emergency
room visits, hospitalizations, unscheduled physician visits,
treatment costs for drug-related adverse events, and rescue
medication (albuterol). Indirect costs (I) included: lost
wages and benefits associated with missed workdays or
school days. All costs are reported in 1998 dollars.
RESULTS: Three hundred twenty-nine patients were ran-
domized to receive ICS (n  111), LTRA (n  107), or PL
(n  111). The cost-effectiveness (CE) ratios in terms of
SFD, were $6.62 (D); $8.86 (D  I) for ICS compared to
$12.08 (D); $14.15 (D  I) for LTRA. The CE ratios for
